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What is the Role of Advanced
Lipoprotein Analysis in Clinical Practice2607Jennifer G. Robinson
2616Michael H. Davidson
Some practitioners use advanced lipid analyses with the goal of better predicting risk and
individualizing therapy. Robinson argues that it remains to be determined whether these tests
incrementally add to cardiovascular risk, or whether treatment strategies guided by, or
targeting these measures, improve cardiovascular outcomes. An accompanying commentary by
Davidson, argues that there is enough evidence that once an individual patient has achieved
their non-high-density lipoprotein-C target of therapy, advanced lipoprotein analysis can help
to determine if atherogenic particle concentrations are also well controlled and if not, therapy
should be adjusted.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY2618Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile DysfunctionJason H. Rogers, Irwin Goldstein, David E. Kandzari, Tobias S. Köhler, Curtiss T. Stinis,
Paula J. Wagner, Jeffrey J. Popma, Michael R. Jaff, Krishna J. Rocha-Singh
Rogers and colleagues evaluated the safety and feasibility of zotarolimus-eluting stent
implantation in the internal pudendal arteries (IPAs) among men with erectile dysfunction
(ED) and a suboptimal response to phosphodiesterase-5 inhibitors (PDE5is). Clinical, duplex
ultrasonographic (DUS), and invasive angiographic factors were used to determine eligibility
for stent therapy. A total of 45 lesions were treated with stents in 30 subjects. Procedural
success was 100% with no major adverse events. The primary feasibility endpoint was
improvement in the International Index of Erectile Function-6 score, which measures
symptoms of erectile dysfunction. At 6 months, 70% of per-protocol treated subjects had a
4 point improvement in IIEF-6 score. In patients with ED refractory to PDE5i,
percutaneous revascularization of the IPA is feasible and associated with clinically meaningful
improvement in both subjective and objective measures of erectile function.
Editorial Comment: Mehdi H. Shishehbor, Femi Philip, page 2628(continued on page A-20)
DECEMBER 25, 2012 (continued) A-20CARDIOMETABOLIC RISK2631Genetic Study Shows Benefits of Lifelong Low LDLBrian A. Ference, Wonsuk Yoo, Issa Alesh, Nitin Mahajan, Karolina K. Mirowska, Abhishek Mewada,
Joel Kahn, Luis Afonso, Kim Allan Williams, Sr., John M. Flack
Ference and colleagues conducted a series of Mendelian randomization studies involving 9
polymorphisms in 6 different genes that have been associated with serum levels of low-density
lipoprotein cholesterol (LDL-C). For each polymorphism, the effect of the allele on LDL-C
and on the risk of coronary heart disease (CHD) was determined. Each exposure allele was
associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C,
with no evidence for heterogeneity of effect. In a meta-analysis combining data from 312,321
participants, long-term exposure to lower LDL-C was associated with a 55% reduction in the
risk of CHD for each 38.7 mg/dl (1 mmol/L) lower LDL-C. This represents a three-fold
greater reduction in the risk of CHD per unit lower LDL-C than that observed during
treatment with a statin started later in life. These results confirm the benefit of lifelong lower
levels of LDL-C.Editorial Comment: Daniel Steinberg, Scott M. Grundy, page 2640CARDIOMETABOLIC RISK2643Childhood Obesity and Vascular PhenotypesMarietta Charakida, Alexander Jones, Emanuela Falaschetti, Tauseef Khan, Nicholas Finer, Naveed Sattar,
Aroon Hingorani, Debbie A. Lawlor, George Davey Smith, John E. Deanfield
Charakida and colleagues examined the associations of birthweight, early growth, and
childhood adiposity with vascular phenotype in pre-pubertal children. Children age 10 to 11
years were tested for flow-mediated dilatation (FMD) and pulse wave velocity (PWV).
Birthweight and weight gain in the first 2 weeks and 2 months were obtained from medical
records. Overweight and obese children had higher heart rate (HR) and systolic blood
pressure (BP). However, obese children had greater brachial diameter, resting and hyperemic
blood flow, higher FMD, and lower arterial stiffness. Birth weight and weight gain in early
life were not associated with vascular phenotype at 10 years of age. Childhood adiposity is
associated with adverse cardiometabolic risk factors, but with better endothelial function and
arterial stiffness at age 9 to 11 years.
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6HEART FAILURE
26536-Min Walk Test Provides Prognostic Utility
Comparable to CPX Testing in Patients With Systolic HFDaniel E. Forman, Jerome L. Fleg, Dalane Kitzman, Clinton A. Brawner, Ann M. Swank,
Robert McKelvie, Robert M. Clare, Stephen J. Ellis, Mark E. Dunlap, Vera Bittner
Fleg and associates compared 6 min walk distance (6MWD) and cardiopulmonary exercise
(CPX) indices (peak oxygen consumption [VO2] and minute ventilation-carbon dioxide
roduction [VE/VCO2] slope) as predictors of all-cause mortality/hospitalization and
ll-cause mortality in patients with systolic heart failure (HF). C-indices were similar for
MWD, peak VO2, and VE/VCO2 slope suggesting similar prognostic discrimination in
both adjusted and unadjusted models. In patients with systolic heart failure, 6MWD and
CPX have similar utility for predicting all cause hospitalization/mortality and all-cause
mortality.Editorial Comment: Stanley A. Rubin, page 2662HEART RHYTHM DISORDERS2664Ventricular Arrhythmias After Cardiac Surgery: Incidence, Predictors, and OutcomesMikhael F. El-Chami, Fadi J. Sawaya , Patrick Kilgo, William Stein IV, Michael Halkos, Vinod Thourani,
Omar M. Lattouf, David B. Delurgio, Robert A. Guyton, John D. Puskas, Angel R. Leon
El-Chami and colleagues investigated the prevalence, predictors, and outcomes of patients
with new-onset post-operative ventricular arrhythmia (POVA) after cardiac surgery. Records
were reviewed from 14,720 consecutive patients undergoing cardiac surgery at a single
institution. POVA occurred in 1.7% of patients, who were on average older with lower left
ventricular ejection fraction, and higher Society of Thoracic Surgeons risk score. POVA was
associated with substantially increased adjusted in-hospital and long-term mortality.
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Allen J. Solomon, Marian C. Limacher, Karen C. Johnson, J. David Curb, Sylvia Wassertheil-Smoller,
Charles B. Eaton
Bertoia and colleagues used data from the Women’s Health Initiative clinical trials to estimate
the annual incidence rate of sudden cardiac death (SCD) and its associated risk factors in
post-menopausal women. The incidence rate of SCD was 2.4 per 10,000 women per year.
Older age, African-American race, tobacco use, higher pulse, higher waist-to-hip ratio,
elevated white blood cell count, history of heart failure, diabetes, history of myocardial
infarction, previous carotid artery disease, and hypertension were independent risk factors for
SCD. Besides traditional risk factors for coronary heart disease, risk factors for SCD in post-
menopausal women include African-American race, higher pulse, higher waist-to-hip ratio,
elevated white blood cell count, and heart failure.EXPEDITED PUBLICATION
2683Transcatheter Aortic Valve Replacement Appears Cost Effective Compared With
Surgical Aortic Valve Replacement in High Risk Patients With Transfemoral AccessMatthew R. Reynolds, Elizabeth A. Magnuson, Yang Lei, Kaijun Wang, Katherine Vilain, Haiyan Li,
Joshua Walczak, Duane S. Pinto, Vinod H. Thourani, Lars G. Svensson, Michael J. Mack, D. Craig Miller,
Lowell E. Satler, Joseph Bavaria, Craig R. Smith, Martin B. Leon, David J. Cohen, on behalf of the
PARTNER Investigators
Reynolds and colleagues evaluated the cost-effectiveness of transcatheter aortic valve
replacement (TAVR) compared with surgical aortic valve replacement (AVR) using data from
the PARTNER Trial. Cumulative 12-month costs (assessed from a US societal perspective)
and quality-adjusted life years (QALYs) were compared separately for the transfemoral (TF)
and transapical (TA) cohorts. In the TF cohort, total 12-month costs were slightly lower with
TAVR, and QALYs were slightly higher; In the TA cohort, 12-month costs were
substantially higher and QALYs tended to be lower. While TAVR was an economically
attractive strategy compared with AVR for patients suitable for TF access, future studies will
be necessary to determine whether improved experience and outcomes with TA-TAVR can
improve its cost effectiveness.
